Free Trial

Solid Biosciences (SLDB) Stock Price, News & Analysis

Solid Biosciences logo
$5.42 -0.10 (-1.81%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$5.43 +0.01 (+0.18%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Solid Biosciences Stock (NASDAQ:SLDB)

Key Stats

Today's Range
$5.21
$5.54
50-Day Range
$2.55
$5.52
52-Week Range
$2.41
$10.37
Volume
1.29 million shs
Average Volume
1.20 million shs
Market Capitalization
$420.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.10
Consensus Rating
Buy

Company Overview

Solid Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

SLDB MarketRank™: 

Solid Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 301st out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Solid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 10 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Solid Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Solid Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Solid Biosciences are expected to grow in the coming year, from ($2.84) to ($2.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Solid Biosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Solid Biosciences is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Solid Biosciences has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Solid Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.28% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Solid Biosciences has recently decreased by 3.23%, indicating that investor sentiment is improving.
  • Dividend Yield

    Solid Biosciences does not currently pay a dividend.

  • Dividend Growth

    Solid Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.28% of the float of Solid Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Solid Biosciences has a short interest ratio ("days to cover") of 5.1.
  • Change versus previous month

    Short interest in Solid Biosciences has recently decreased by 3.23%, indicating that investor sentiment is improving.
  • News Sentiment

    Solid Biosciences has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Solid Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    Only 19 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
  • MarketBeat Follows

    31 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 72% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Solid Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.90% of the stock of Solid Biosciences is held by insiders.

  • Percentage Held by Institutions

    81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Solid Biosciences' insider trading history.
Receive SLDB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SLDB Stock News Headlines

Photo of Solid Biosciences logo and genes
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
After a second patient passed away, Sarepta Therapeutics crashed. Solid Biosciences rose over 10% in response. Wall Street sees big upside in both names.
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
SLDB Solid Biosciences Inc. - Seeking Alpha
See More Headlines

SLDB Stock Analysis - Frequently Asked Questions

Solid Biosciences' stock was trading at $4.00 at the beginning of the year. Since then, SLDB shares have increased by 35.5% and is now trading at $5.42.

Solid Biosciences Inc. (NASDAQ:SLDB) posted its quarterly earnings results on Thursday, May, 15th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.06.

Solid Biosciences's stock reverse split on the morning of Friday, October 28th 2022.The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Solid Biosciences (SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Solid Biosciences' top institutional investors include Pallas Capital Advisors LLC (0.01%). Insiders that own company stock include Perceptive Advisors Llc, Alexander Cumbo, Kevin Tan, Carl Ashley Morris, David T Howton, Jessie Hanrahan, Ilan Ganot, Gabriel Brooks, Paul Herzich and Clare Kahn.
View institutional ownership trends
.

Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/15/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SLDB
CIK
1707502
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+178.6%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.99)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$124.70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-68.15%
Return on Assets
-55.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.89
Quick Ratio
10.89

Sales & Book Value

Annual Sales
$8.09 million
Price / Sales
51.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.43 per share
Price / Book
1.58

Miscellaneous

Outstanding Shares
77,510,000
Free Float
76,042,000
Market Cap
$420.10 million
Optionable
Optionable
Beta
2.34
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:SLDB) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners